Microglial cells are the resident macrophages and intrinsic arm of the central nervous system innate immune defense. Microglial cells become activated in response to injury, infection, environmental toxins, and other stimuli that threaten neuronal survival. Therefore, regulating microglial activation may have therapeutic benefits that lead to alleviating the progression of inflammatory-mediated neurodegeneration. In the present study, we investigated the effect of glaucocalyxin A (GLA) isolated from Rabdosia japonica on the production of pro-inflammatory mediators in lipopolysaccharide (LPS)-stimulated primary microglia and BV-2 cells. GLA significantly inhibited LPS-induced production of nitric oxide and reversed the morphological changes in primary microglia. Further, GLA suppressed expression of inducible nitric oxide synthase and cyclooxygenase-2 dose-dependently at the mRNA and protein levels. The production of proinflammatory cytokines such as tumor necrosis factor-α, interleukin-1β (IL)-1β, and IL-6 were inhibited by suppressing their transcriptional activity. Furthermore, GLA suppressed nuclear factor-κB activation by blocking degradation of IκB-α and inhibited the induction of lipocalin-2 expression in LPS-stimulated BV-2 cells. Mechanistic study revealed that the inhibitory effects of GLA were accompanied by blocking the p38 mitogen activated protein kinase signaling pathway in activated microglia. In conclusion, given that microglial activation contributes to the pathogenesis of neurodegenerative diseases, GLA could be developed as a potential therapeutic agent for treating microglia-mediated neuroinflammatory diseases.
Citation: Kim B-W, Koppula S, Hong S-S, Jeon S-B, Kwon J-H, Hwang B-Y, et al. (2013) Regulation of Microglia Activity by Glaucocalyxin-A: Attenuation of Lipopolysaccharide-Stimulated Neuroinflammation through NF-κB and p38 MAPK Signaling Pathways. PLoS ONE 8(2): e55792. https://doi.org/10.1371/journal.pone.0055792
Editor: Michelle L. Block, Virginia Commonwealth University, United States of America
Received: October 4, 2012; Accepted: December 30, 2012; Published: February 5, 2013
Copyright: © 2013 Kim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0014923) and also supported by the Regional Innovation Center (RIC) Program of the Ministry of Knowledge Economy through the Bio-Food & Drug Research Center at Konkuk University, Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Dysregulation of the neuroimmune system has been suggested to play a decisive role in the pathogenesis of several neurodegenerative disorders. Microglia, the resident immune cells of the central nervous system, become activated and induce significant and highly detrimental neurotoxic effects by excessively producing a large array of cytotoxic and proinflammatory factors , , . Microglia enhance and amplify neuronal damage induced by pathological stimuli and toxins when they are over activated, which, in turn, induces more widespread damage to neighboring neurons through a process called reactive microgliosis , .
Therefore, the ideal therapeutic approach would involve early attenuation of the microglial response to levels that are no longer deleterious to the neuronal environment, and drugs targeting specific aspects of the microglia-related cascade may prove successful. Lipopolysaccharide (LPS) is a common toxin used to investigate the impact of inflammation on neuronal death, and microglial cells are necessary for LPS-induced neurotoxicity . BV-2 microglial cells respond to the LPS endotoxin by synthesizing inflammatory factors such as nitric oxide (NO), cyclooxygenase-2 (COX-2), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, and IL-6. These microglial products are thought to be responsible for neuroglia-mediated neurotoxicity .
We isolated and purified glaucocalyxin A (GLA) from Rabdosia japonica (R. japonica) var. galucocalyx (Labiatae) as part of our systematic approach to drug discovery and identifying potential compounds that ameliorate the inflammatory-mediated events seen in neurodegenerative diseases. R. japonica is a perennial herb that is distributed widely in East Asia, and the entire R. japonica extract has been used traditionally as a folk medicine for treating gastrointestinal disorders, tumors, and inflammatory diseases , . In this study, the anti-neuroinflammatory effect of GLA and the underlying mechanisms involved were investigated in LPS-stimulated microglial cells.
Materials and Methods
LPS (E. coli 0111:B4), Tween-20, bovine serum albumin (BSA), dimethyl sulfoxide (DMSO), p-nitrophenyl phosphate, 3-(4, 5-dimethylthiazol-2-yl)-2, 5- phenyltetrazolium bromide (MTT), and pyrrolidine dithiocarbamate (PDTC) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s Modified Eagle Medium, fetal bovine serum, phosphate buffered saline (PBS), and other cell culture reagents were obtained from Gibco/Invitrogen (Grand Island, NY, USA). Protease inhibitor cocktail tablets and phosphatase inhibitor cocktail tablets were supplied by Roche (Roche, Indianapolis, IN, USA). COX-2, nuclear factor (NF)-κB p65, and nucleolin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Inducible nitric oxide synthase (iNOS), IκB-α, phospho (p)-IκB-α, p38, p-p38, and β-actin were supplied by Cell Signaling Technology (Danvers, MA, USA). The mouse lipocalin-2 (LCN2) antibody was purchased from R&D Systems (Minneapolis, MN, USA). Nuclear extract kit was purchased from Thermo Scientific (Rockford, IL, USA), prostaglandin E2 (PGE2) enzyme-linked immunoassay (EIA) kit was obtained from Cayman Chemical Co. (Ann Arbor, MI, USA), and nitric oxide synthase (NOS) 2 and inducible NOS (iNOS) 2 EIA kits were purchased from Uscn Life Science Inc. (Wuhan, China).
The aerial parts of R. japonica were collected from the herb garden at Chungbuk National University, Cheongju, Korea. The plant material was authenticated by a taxonomist, and a voucher specimen (CBNU0909) was deposited at the herbarium of the College of Pharmacy, Chungbuk National University, Korea. The aerial parts of R. japonica were shade dried and extracted three times with methanol at room temperature with a starting material of 500 g. The solvent obtained was evaporated under reduced pressure, and the final yield (35 g) was freeze dried and stored in a refrigerator.
Isolation of GLA using Bioactivity-guided Fractionation
The freeze dried extract of the R. japonica aerial parts was suspended in water and partitioned with n-hexane and dichloromethane (CH2Cl2), successively. The CH2Cl2 fraction was subjected to reverse-phase silica gel (ODS) column chromatography using, water (H2O) and acetonitrile (MeCN) gradient to produce three fractions named RJ-01, RJ-02, and RJ-03. The active subfraction RJ-02 was further separated by preparative high performance liquid chromatography (HPLC) [J’-sphere ODS H-80 150×20 mm; MeCN/H2O (4∶6); flow rate: 6.0 mL/min] to produce a white amorphous powder named GLA (16.2 mg, Fig. 1A). The electrospray ionization mass spectroscopy (EI-MS) spectrum was obtained on a VG Autospec Ultima mass spectrometer. 1H, 13C nuclear magnetic resonance (NMR), distortionless enhancement by polarization transfer, and heteronuclear multiband connectivity spectra were recorded using a Bruker DRX 500 NMR spectrometer. The GLA structure (Fig. 1B) was analyzed by NMR spectroscopy and was confirmed by comparison of its physicochemical and spectroscopic data as reported previously . GLA: white amorphous powder; EI-MS m/z: 332 [M]+; 1H-NMR (500 MHz, pyridine-d5) δ: 6.31 (1H, s, H-17a), 5.38 (1H, s, H-17b), 5.06 (1H, br s, H-14), 4.71 (1H, dd, J = 11.5, 5.0 Hz, H-7), 3.24 (1H, br s, H-13), 2.51-2.43 (2H, m, H-2), 2.08 (1H, m, H-12α), 2.01 (1H, m, H-12β), 1.73 (1H, overlap, H-1α), 1.66 (1H, overlap, H-5), 1.63 (2H, m, H-6), 1.44 (1H, br s, H-9), 1.40 (2H, m, H-11), 1.20 (1H, m, H-1β), 1.07 (6H, s, Me-18, 19), 1.00 (3H, s, Me-20); 13C-NMR (125 MHz, pyridine-d5) δ: 215.9 (C-3), 207.6 (C-15), 149.6 (C-16), 116.5 (C-17), 75.3 (C-14), 73.5 (C-7), 61.6 (C-8), 53.3 (C-9), 51.5 (C-5), 46.8 (C-4), 46.7 (C-13), 38.9 (C-10), 38.3 (C-1), 34.0 (C-2), 31.1 (C-6), 30.8 (C-12), 27.4 (C-18), 21.1 (C-19), 18.4 (C-11), 18.1 (C-20).
Primary microglia was cultured from the cerebral cortices or substantia nigra of 1- to 3-day-old Sprague-Dawley rats. Briefly, tissues were triturated into single cells in MEM containing 10% FBS and were plated in 75-cm2 T-flasks (0.5 hemisphere/flask) for 2 weeks. The microglia were detached from the flasks by mild shaking and applied to a nylon mesh to remove astrocytes and cell clumps. Cells were plated in 6-well plates (5×105 cells/well), 60-mm2 dishes (8×105 cells/dish), or 100-mm2 dishes (2×106 cells/dish). One hour later, the cells were washed to remove unattached cells before use in experiments. The purity of microglia cultures was assessed using CD-11b antibody and more than 90% of cells were stained positively.
The BV-2 cell (a mouse microglial cell line) was originally developed by Dr. V. Bocchini (University of Perugia, Perugia, Italy), and it was generously provided to us by Dr. K. Suk (Kyung-Pook National University, Daegu, Korea). The immortalized murine BV-2 cell line that exhibits both the phenotypic and functional properties of the reactive microglia cells  were grown and maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 5% heat-inactivated FBS, 50 µg/mL of penicillin–streptomycin and maintained in a humidified incubator at 37°C, with 5% CO2. Primary microglial cells were seeded at a density of 5×105 cells/mL and BV-2 cells at 5×104 cells/mL. In separate experiments, primary microglia were pretreated for 1 h with various concentrations of GLA (0.1 and 0.5 µM) and BV-2 cells were treated with 0.1, 1, and 5 µM GLA before incubation in LPS-containing medium (25 ng/mL and 100 ng/mL respectively (E. coli 0111:B4, Sigma).
NO Production Assay
NO production was assayed by measuring the levels of nitrite, the stable NO metabolite, in culture media. Nitrite accumulation in media was determined using a colorimetric assay with Griess reagent . Cells (5×104 cells/mL) were seeded in 96-well plates in 100 µL culture medium and stimulated with LPS (25 or 100 ng/mL) for 24 h. A 50 µL aliquot of culture supernatant was reacted with an equal volume of Griess reagent (0.1% naphthylethylenediamine and 1% sulfanilamide in 5% H3PO4) in 96-well plates for 10 min at room temperature in the dark. Nitrite concentrations were determined using standard solutions of sodium nitrite prepared in medium. Absorbance was determined at 540 nm using a microplate reader.
iNOS Enzyme Activity Assay
To obtain the total cell lysate, 80 µL of RIPA buffer was added to the BV-2 cells (5×105 cells/mL) cultured in 6-well plates. The cells were scraped, incubated for 10 min on ice and centrifuged at 14,000×rpm for 10 min at 4°C. The protein concentration was determined by the DC protein assay from Bio-Rad (Hercules, CA, USA), and 10 µg of whole cell lysate were used for iNOS activity. The iNOS enzyme activity in lysate were determined spectrophotometrically (Tecan Trading AG, Switzerland) at 450 nm. Each experiment was performed in triplicate.
Culture supernatants were collected by centrifugation, and the PGE2 concentration was determined by enzyme immunoassay using a PGE2 EIA kit. The absorbance at 420 nm was determined using a microplate reader (Molecular Devices, Sunnyvale, CA, USA). Each experiment was performed in triplicate.
Reverse Transcription-polymerase Chain Reaction (RT-PCR)
Total RNA was extracted using TRIZOL (Invitrogen, Carlsbad, CA, USA). RNA (2.5 µg) was reverse-transcribed using a Superscript™-III kit (Invitrogen), according to the manufacturer’s instruction. PCR amplification was carried out in a 50 µL PCR reaction mixture containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgCl2, 20 pmol of each primer set, two units of Taq DNA polymerase (Bioneer Co., Daejeon, Korea), 0.2 mM dNTPs, and 2 µL of cDNA. The PCR conditions were described previously .
Western Blot Analysis
Cells were lysed on ice in lysis buffer consisting of 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM EDTA (Sigma), 1% protease inhibitor cocktail, and 1% phosphatase inhibitor cocktail (Roche). After centrifugation, the protein concentration of the supernatant was assayed using a Bio-Rad DC Protein Assay kit. Lysate samples containing 20 or 40 µg of protein were fractionated by SDS-10% polyacrylamide gel electrophoresis and then electroblotted onto polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). The membranes were probed with primary antibodies to anti-iNOS, anti-IκB-α, anti-phospho-IκB-α (1∶1000), anti-β-actin (1∶2000) anti-COX-2, anti p65 (1∶1000), and anti nucleolin (1∶500). The blots were visualized by a PowerOpti-ECL (Animal Genetics Inc, Tallahassee, FL, USA) detection system according to the manufacturer’s procedure and the antibody-specific bands were scanned by a Luminescent Analyzer, LAS-3000 and quantified using Fuji Multigage software V3.1 (Fuji, Tokyo).
Double-immunofluorescence Labeling Assay
Primary microglia were plated onto round coverslips (Fisher Scientific) and fixed with ice-cold 100% methanol. Fixed microglia were permeabilized with PBS containing 0.1% Triton X-100 (PBS-T) and blocked with 1% BSA (Sigma-Aldrich). The product was then washed with PBS-T and incubated overnight at 4°C with OX-42 (1/100) antibody. Samples were rinsed three times for 5 min with PBS-T. Each coverslip was mounted on slides with mounting solution, and the cells were observed with a Carl Zeiss LSM510 confocal microscope (Carl Zeiss, Oberkochen, Germany).
BV-2 microglia cells were cultured on sterile cover slips in 24-well plates and treated with compounds and LPS to detect the intracellular location of the NF-κB p65 subunit. At 60 min after the LPS treatment, the cells were fixed with methanol for 20 min at -20°C and washed with PBS for 5 min. The fixed cells were then permeabilized with 0.5% Triton X-100 in PBS for 1 h at room temperature, washed with 0.05% Tween-20 in PBS for 10 min, followed by 0.05% Tween-20/1% BSA in PBS for 5 min. The permeabilized cells were then treated with 1 mg/ml monoclonal mouse anti-human NF-κB (p65) for 60 min at room temperature and washed with 0.05% Tween-20/1% BSA in PBS for 5 min. The cells were then incubated in a 1∶2000 dilution of Alexa Fluor 568-labeled goat anti-mouse antibody (Invitrogen) for 60 min at room temperature and washed with 0.05% Tween-20 in PBS for 5 min, followed by PBS for 5 min. The cells were then stained with 0.1 µM of Hoechst (Invitrogen) staining solution for 20 min at 37°C and then washed. Finally, all images were captured with a Carl Zeiss Axio40 fluorescence microscope.
Data are presented as means ± standard errors of at least three separate experiments conducted in triplicate. Comparisons between groups were analyzed using One-Way analysis of variance (ANOVA) followed by Bonferroni post hoc multiple comparisons test with using software Graphpad Prism V5.01. (GraphPad Software Inc., San Diego, CA, USA). P-values less than 0.05 were considered to be statistically significant.
Inhibition of NO Production by GLA in LPS-stimulated Primary Microglial and BV-2 Cells
To evaluate the effect of GLA on LPS-induced NO production, primary microglial cells were pre-treated for 1 h with different concentrations of GLA (0.1 or 0.5 µM), followed by LPS (25 ng/mL) for 24 h, and the levels of NO in culture media were determined using the Griess assay. As shown in Fig. 2A, when primary microglial cells were stimulated with LPS (25 ng/mL) for 24 h, the levels of nitrite, a stable oxidized product of NO, increased markedly in the culture medium to 16.39±0.55 µM compared with the control at 1.72±0.39 µM. When pre-treated with GLA at different doses, the LPS-induced increase in NO production decreased to 12.19±0.19 µM and 2.09±0.33 µM respectively, in a concentration-dependent manner. Furthermore, we investigated whether GLA had similar inhibitory effects in BV-2 cells. As shown in Fig. 2B, LPS treatment (100 ng/mL) alone markedly induced NO production (24.61±0.82 µM) in BV-2 cells compared to that in the control (2.55±0.41 µM). Pre-treatment with GLA (0.1, 1, or 5 µM) significantly suppressed the increase in NO production to 20.77±0.65, 9.96±0.45, and 3.49±0.06 µM respectively. The morphological changes of normal cultured primary microglia observed using confocal microscopy showed round or amoeboid shape, whereas LPS (25 ng/mL)-stimulated primary microglia exhibited marked changes from a round or amoeboid shape to a multipolar rod or ramified morphology. Pretreatment with GLA at 0.1 µM reversed this altered changes in morphology (Fig. 2C).
A: Rat primary microglial cells were pre-treated with the indicated concentrations (0.1 µM or 0.5 µM) of GLA for 1 h before incubating with LPS (25 ng/mL) for 24 h. Nitrite levels were measured in culture media by the Griess reaction. B: BV-2 microglia cells were pre-treated with the indicated concentrations of GLA (0.1, 1, or 5 µM) for 1 h before stimulating with LPS (100 ng/mL) for 24 h. C: Primary microglial cells were treated with GLA (0.1 µM) and LPS(25 ng/ml) for 18 h. Cells were stained with CD11b (OX-42) antibody and changes in morphology was observed using confocal microscopy (scale bar, 20 µm). Data are mean ± S.E.M. (n = 3) for three independent experiments. #P<0.001, compared with control group; *P<0.05, **P<0.01 and ***P<0.001 compared with LPS-treated group by One-Way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test.
Our results indicate that GLA has a potent effect for inhibiting increased NO production in LPS-stimulated primary microglia and BV-2 cells. GLA treatment alone at the indicated concentrations did not alter overall production of NO in primary microglia or BV-2 cells.
GLA Attenuates LPS-stimulated Increase in iNOS Levels and Enzyme Activity in Microglial Cells
As shown in Fig. 3A, primary microglia showed increased protein levels when stimulated with LPS (25 ng/mL). Pre-treatment with GLA at indicated concentrations (0.1 and 0.5 µM) attenuated this increase significantly. Further BV-2 cells stimulated with LPS resulted in increased iNOS expression and subsequent iNOS enzyme production. Pre-treatment with GLA at various concentrations (0.1, 1, or 5 µM) significantly inhibited iNOS mRNA and protein levels (Fig. 3B and 3C), compared with those in the LPS-treated control. In addition, GLA reduced LPS-stimulated iNOS enzyme activity in BV-2 cells significantly (p<0.001). The data showed a significant reduction (68.71±5.36%) in enzyme activity following GLA treatment (5 µM) in LPS-treated BV-2 cells (Fig. 3C).
Cells were pre-treated with the indicated concentrations of GLA for 1 h before incubating with LPS (25 ng/mL or 100 ng/mL) for 18 h A: Primary microglia, B: BV-2 microglia. Lysates were analyzed by immunoblotting with an anti-iNOS antibody. Representative quantification data were shown in the lower panel. Results are expressed as a ratio of iNOS to β-actin. C: BV-2 cells were pre-treated with the indicated concentrations of GLA for 1 h before incubating with LPS (100 ng/mL) for 6 h. The total RNA was isolated and iNOS mRNA level was determined by RT-PCR. Quantification data are shown in the lower panel. Results are expressed as a ratio of iNOS to GAPDH. D: BV-2 microglial cells were pre-treated with the indicated concentrations of GLA for 1 h before incubating with LPS (100 ng/mL) for 18 h. iNOS activity was analyzed with enzyme immunoassay kit. Data are mean ± S.E.M. (n = 3) for three independent experiments. #P<0.001 compared with control group; *P<0.05, **P<0.01 and ***P<0.001 compared with LPS-treated group by One-Way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test.
Attenuation of COX-2, PGE2 and Proinflammatory Cytokine Levels by GLA in LPS-Stimulated Microglial Cells
LPS stimulation to primary microglia led to a significant increase in COX-2 protein levels when compared to controls (p<0.001). Pre-treatment with GLA at indicated concentrations (0.1 and 0.5 µM) inhibited the LPS-stimulated increase in COX-2 levels (p<0.01 and p<0.001, respectively) significantly (Fig. 4A). In LPS-stimulated BV-2 cells, GLA significantly attenuated both protein level and mRNA expression in a concentration dependent manner (Fig. 4B and 4C). In addition, treatment of BV-2 cells with LPS for 18 h, caused nearly a 2.7-fold increase in PGE2 release when compared with untreated controls. However, pre-treatment with GLA inhibited the LPS-stimulated increase in the production of PGE2 in a dose-dependent fashion (Fig. 4D).
Cells were pre-treated with the indicated concentrations of GLA for 1 h before incubating with LPS (25 ng/mL or 100 ng/mL) for 18 h A: Primary Microglia, B: BV-2 cells. Results are expressed as a ratio of COX-2 to β-actin. Representative quantification data was shown in the lower panel. C: Cells were pre-treated with the indicated concentrations of GLA for 1 h and then stimulated with LPS (100 ng/mL) for 6 h. Total RNA was prepared and COX-2 mRNA level was determined by RT-PCR. Results are expressed as the ratio of COX-2 to GAPDH. Quantification data are shown in the lower panel. D: PGE2 levels were analyzed with an enzyme immunoassay kit. Absorbance was measured at 420 nm spectrophotometrically. Data are mean ± S.E.M. (n = 3) for three independent experiments. #P<0.001 compared with control group; *P<0.05 and ***P<0.001 compared with LPS-treated group by One-Way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test.
Pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 play central roles in microglia-mediated inflammation. Therefore, the effects of GLA on proinflammatory cytokine production in LPS-stimulated BV-2 microglial cells were evaluated. BV-2 cells were incubated with GLA (0.1, 1.0, or 5.0 µM) in the presence or absence of LPS (100 ng/mL). TNF-α, IL-1β, and IL-6 were not expressed at detectable levels under normal culture conditions, but the expression of these cytokines was significantly upregulated after 6 h of treatment with LPS (100 ng/mL). Pre-treatment with GLA significantly inhibited LPS-induced TNF-α, IL-1β, and IL-6 production, compared with that in the LPS-treated controls (Fig. 5A). The representative quantification data revealed that LPS-stimulated proinflammatory cytokine mRNA levels (TNF-α, IL-1β and IL-6) were significantly decreased following GLA treatment (Fig. 5B, 5C and 5D, respectively), suggesting that GLA negatively regulates TNF-α, IL-1β, and IL-6 production.
A: Cells were pre-treated with the indicated doses of GLA for 1 h before LPS (100 ng/mL) treatment. The levels of TNF-α, IL-1β, and IL-6 mRNA were determined by RT-PCR. Representative densitometry analysis of B: TNF-α, C: IL-1β, and D: IL-6 compared with GAPDH mRNA, respectively. Data are mean ± S.E.M. (n = 3) for three independent experiments. #P<0.001 compared with the control group; **P<0.01 and ***P<0.001 compared with the LPS-treated group by One-Way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test.
Effect of GLA on LPS-induced NF-κB Nuclear Translocation and IκB-α Degradation in Microglial Cells
Mounting evidence suggests that increased production of pro-inflammatory cytokines by LPS stimulation was mediated by the activation of NF-κB. Reports also revealed that NF-κB activation includes degradation of IκB-α through phosphorylation and subsequent nuclear translocation of p65 subunit of NF-κB , , , . NF-κB regulates and plays an essential role in LPS-induced expressional levels of iNOS, COX-2 and various proinflammatory cytokines , . Therefore, to further elucidate the mechanism of GLA, NF-κB (p65) transcription factor was examined in LPS-stimulated BV-2 microglial cells. As shown in Fig. 6A, immunofluorescence assay revealed that GLA might regulate the LPS-stimulated NF-κB activation. LPS-stimulated BV-2 cells were pre-treated with GLA for 30 min and NF-κB activity was evaluated by nuclear translocation of the p65 subunit of NF-κB (Fig. 6B). Further, the phosphorylation of IκB-α was also inhibited by GLA treatment in both primary microglia and BV-2 cells significantly (Fig. 7A and 7B). In addition, the effect of GLA-inhibited IκB-α phosphorylation was consistent and showed synergistic action when co-treated with specific NF-κB inhibitor, PDTC on LPS-stimulated BV-2 microglial cells (p<0.001, Fig. 7C). LPS-induced NO production also decreased prominently when GLA was co-treated with PDTC (p<0.001, Fig. 7D). These results indicate that GLA suppressed the production of NO, iNOS, COX-2 and pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and this inhibition might be through regulation of NF-κB activation and degradation of IκB-α in LPS-stimulated BV-2 cells.
A: BV-2 microglia cells were seeded at a density of 5×104cells/well on 24-well plates. Cells were stimulated with LPS (100 ng/mL) in the absence or presence of GLA (5 µM) added 1 h before stimulation. At 30 min after adding the LPS, the sub-cellular location of the NF-κB p65 subunit was determined by immunofluorescence assay. B: Cells were treated with the indicated dose of GLA 30 min before LPS (100 ng/mL) treatment. Total nuclear protein was subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting using anti-NF-κB p65. Densitometry analysis of NF-κB p65 is shown in the lower panel. Results are expressed as a ratio of NF-κB p65 to nucleolin. Data are mean ± S.E.M. (n = 3) for three independent experiments. # P<0.001 compared with control group; *P<0.05, **P<0.01, and ***P<0.001 compared with LPS-treated group by One-Way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test.
Cells were treated with the indicated dose of GLA for 1 h before LPS (100 ng/mL) treatment for 30 min. A: Primary Microglia, B: BV-2 cells C: BV-2 cells were pre-treated with 20 µM PDTC for 2 h before 5 µM GLA was added for 1 h and before incubating with LPS (100 ng/mL) for 30 min. Lysates were analyzed by immunoblotting with an anti p-IκB-α/IκB-α antibody. Representative densitometric analyses was shown in the lower panels. Results are expressed as a ratio of p-IκB-α to IκB-α. D: BV-2 microglial cells were pre-treated with 20 µM PDTC for 2 h before 5 µM GLA was added and 1 h before incubating with LPS (100 ng/mL) for 24 h. Data are mean ± S.E.M. (n = 3) for three independent experiments. #P<0.001 compared with control group; *P<0.05, **P<0.01, and ***P<0.001 compared with LPS-treated group by One-Way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test.
GLA Inhibits p38 Mitogen-activated Protein Kinase (MAPK) Phosphorylation in LPS-Stimulated Microglia Cells
The p38 mitogen activated protein kinase (p38 MAPK) plays a central role in the inflammatory cytokine response to immune challenge and consequently the development of sickness behavior . To assess activation of this signaling kinase the levels of phosphorylated p38 MAPKs were determined in LPS-stimulated primary microglia and BV-2 cells. Pretreatment with GLA at indicated concentrations significantly inhibited LPS-stimulated p38 phosphorylation in primary microglial cells (p<0.05 and p<0.00, Fig. 8A). Consistent with primary microglial data GLA pre-treatment (0.5, 1.0 and 5.0 µM) also significantly inhibited p38 MAPK phosphorylation in BV-2 cells (Fig. 8B).
Cells were pre-treated with indicated doses of GLA for 1 h before LPS treatment (100 ng/mL) for 30 min. A: Primary Microglia, B: BV-2 microglial cells. Total protein was subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting using anti-p38 MAPKs. Representative densitometric analysis of the p38 bands were shown in the lower panel. Results are expressed as a ratio of p-p38 to total p38. C: Cells were pre-treated with the indicated doses of GLA for 1 h before LPS (100 ng/mL) treatment. LCN-2 mRNA levels were determined by RT-PCR. GAPDH was used as an internal control for the RT-PCR analysis. Representative quantification data was shown in the lower panel. Results are expressed as a ratio of LCN-2 to GAPDH. Data are mean ± S.E.M. (n = 3) for three independent experiments. #P<0.001 compared with control group; *P<0.05, **P<0.01, and ***P<0.001 compared with LPS-treated group by One-Way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test.
GLA Suppresses LPS-induced Lipocalin-2 (LCN-2) Expression in BV-2 Cells
LCN-2 plays an important role as a mediator of microglial activation in response to diverse stimuli, including LPS , . Recent reports have revealed that LCN-2 is induced by oxidative stress , and that it sequesters iron to protect the host from bacterial infection , . LCN-2 suppresses cytokine production induced by LPS in macrophages  and regulates microglia activation and death in an autocrine manner . We examined whether GLA could influence LCN-2 activation by RT-PCR analysis. As a result, LPS increased LCN-2 mRNA levels and GLA reduced LPS-induced LCN-2 mRNA expression (Fig. 8C).
In the present investigation, GLA showed a strong inhibition of microglia mediated deleterious consequences and possess anti-neuroinflammatory effects in LPS-stimulated primary microglia and BV-2 cells in several aspects. GLA inhibited NO production and restored the morphological changes observed in LPS-stimulated primary microglia. Furthermore, GLA inhibited LPS-induced NO and PGE2 production by suppressing iNOS and COX-2 mRNA and protein expression in BV-2 cells. The inhibitory effects of GLA might be regulated via NF-κB activation, translocation of NF-κB from the cytoplasm to the nucleus, and inhibiting LCN-2 expression, which were accompanied by blocking of the p38 MAPK signaling pathway in activated microglia.
Microglia-mediated neuroinflammation tends to be progressive and is the major component enhancing ongoing neurodegeneration. Overactivation and dysregulation of microglia via infection or injury can result in disastrous neurotoxic consequences such as release of proinflammatory cytokines, free radicals, and eicosanoids. These factors are believed to contribute to microglia-mediated neurodegeneration , , . Although endogenous protective regulatory signals such as neuropeptides , , , cannabinoids , , , and anti-inflammatory cytokines (IL-1β and transforming growth factor-β)  in the brain inhibit microglial overactivation, the excessive inflammatory response might result in microglia initiating neuronal death and drive the progressive nature of neurodegenerative disease. Therefore, regulation of microglial activation could reduce neuroinflammation and further neuronal cell damage.
Activation of microglia is pivotal in the initiation of neuroinflammation. Prolonged activation of microglial cells leads to excessive release of NO by iNOS in the brain. NO, an important regulatory mediator involved in cell survival and death exerts a number of pro-inflammatory effects during several physiological and pathological processes. This inflammatory response is believed to be associated with several progressive neurodegenerative diseases . COX-2 is upregulated in response to various inflammatory stimuli including overproduction of PGE2. Upregulation of COX-2 contributes to the development of many chronic inflammatory diseases , . Therefore, agents that inhibit the release of NO and attenuate iNOS and COX-2 expression could be beneficial for preventing and delaying the progression of neuroinflammatory disease. In the present study, GLA treatment to primary microglia and BV-2 cells stimulated by LPS effectively decreased iNOS and COX-2 levels and the release of their respective end-products, NO and PGE2. This inhibition exhibited by GLA may be attributed to suppression of iNOS and COX-2 mRNA transcription and a subsequent reduction in protein expression. Furthermore, GLA exhibited significant inhibitory effects on NO production and restored the morphological changes observed in LPS-stimulated primary microglia.
The transcription factor NF-κB is a pleiotropic regulator of diverse genes involved in the immune and inflammatory responses. NF-κB activates several cellular signal transduction pathways that are involved in the production of iNOS, COX-2, and various cytokines , , . The promoter region of the murine gene encoding iNOS and COX-2 contains NF-κB binding motifs. Activation of NF-κB results in phosphorylation, ubiquitination, and proteasome-mediated degradation of IκB proteins, followed by nuclear translocation. LPS has also been reported to activate NF-κB in microglia. As the expression of these proinflammatory mediators is modulated by NF-κB, blocking NF-κB transcriptional activity may be an important target for treating inflammatory diseases. Our findings show that GLA treatment blocked the degradation of IκB and of NF-κB nuclear translocation in BV-2 microglia stimulated by LPS, suggesting that the effects of GLA on the production of inflammatory mediators and cytokines are at least partially mediated by suppression of NF-κB signaling. Moreover, the inhibition of NF-κB transcriptional activity by GLA was consistent with the effect of the specific NF-κB inhibitor PDTC  when examined simultaneously in LPS-stimulated BV-2 microglial cells.
LCN-2 has diverse cellular functions such as iron delivery , , regulation of cell differentiation and migration , , cell death/survival , , and a role in inflammatory processes . A recent study showed that LCN-2 is involved in the regulation of inflammation and cancer . Thus, suppressing LCN-2 expression could modulate neuroinflammation. LCN-2 is strongly induced by the pro-inflammatory cytokine IL-1β via NF-κB activation , . Increased levels of LCN2 are suggested to be a marker of inflammation. Therefore inhibiting NF-κB activation might regulate the induction of LCN-2 expression and help mitigate inflammatory processes. Data from our study revealed that GLA suppressed LCN-2 expression in LPS-stimulated BV-2 cells.
MAPKs are also involved in LPS-induced COX-2 and iNOS production via control of NF-κB activation in microglial cells , . One of the important MAPK families, p38, is positively related to LPS signaling in microglial cells, which respond to pro-inflammatory cytokines , . Moreover, p38 MAPK is a key mediator of cellular stressors such as inflammation and apoptosis. Both in vitro and in vivo studies have shown that p38 MAPK regulates the production of the pro-inflammatory cytokines, NO, and PGE2 by increasing cytokine release or messenger RNA transcription , . Earlier reports revealed that inhibitors of p38 MAPK (SB203580) reduce LPS-induced iNOS protein levels , . Results from our study indicate that GLA-mediated inhibition of p38 MAPK activation may also be a possible mechanism underlying its inhibitory action on iNOS, COX-2, and pro-inflammatory cytokines expression as well as NO production in LPS-stimulated BV-2 cells.
In conclusion, GLA showed significant anti-neuroinflammatory actions in microglial cells regulating via NF-κB and p38 MAPK Signaling Pathways. Given that microglial activation and the consequent release of various inflammatory components contributes to neurodegeneration, GLA could be developed as a potential therapeutic agent for treating microglia-mediated neuroinflammatory diseases.
Conceived and designed the experiments: DKC BWK EJP. Performed the experiments: BWK SSH SBJ JHK. Analyzed the data: DKC BWK SK. Contributed reagents/materials/analysis tools: DKC BYH EJP. Wrote the paper: DKC BWK SK.
- 1. Colton CA, Gilbert DL (1987) Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett 223: 284–288.
- 2. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW (1993) Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 150: 2659–2667.
- 3. Moss DW, Bates TE (2001) Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. Eur J Neurosci 13: 529–538.
- 4. Block ML, Hong JS (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76: 77–98.
- 5. Teismann P, Tieu K, Cohen O, Choi DK, Wu DC, et al. (2003) Pathogenic role of glial cells in Parkinson’s disease. Mov Disord 18: 121–129.
- 6. Qin L, Liu Y, Qian X, Hong JS, Block ML (2005) Microglial NADPH oxidase mediates leucine enkephalin dopaminergic neuroprotection. Ann N Y Acad Sci 1053: 107–120.
- 7. Jeohn GH, Cooper CL, Jang KJ, Liu B, Lee DS, et al. (2002) Go6976 inhibits LPS-induced microglial TNFalpha release by suppressing p38 MAP kinase activation. Neuroscience 114: 689–697.
- 8. Hong SS, Lee SA, Han XH, Hwang JS, Lee C, et al. (2008) ent-Kaurane diterpenoids from Isodon japonicus. J Nat Prod 71: 1055–1058.
- 9. Sun HD, Huang SX, Han QB (2006) Diterpenoids from Isodon species and their biological activities. Nat Prod Rep 23: 673–698.
- 10. Kim D, Chang R, Shen XY, Chen YP, Sun HD (1992) Diterpenoids from Rabdosia japonica Phytochemistry. 31: 697–699.
- 11. Bocchini V, Mazzolla R, Barluzzi R, Blasi E, Sick P, et al. (1992) An immortalized cell line expresses properties of activated microglial cells. J Neurosci Res 31: 616–621.
- 12. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, et al. (1982) Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126: 131–138.
- 13. Kim BW, Koppula S, Kim IS, Lim HW, Hong SM, et al. (2011) Anti-neuroinflammatory activity of Kamebakaurin from Isodon japonicus via inhibition of c-Jun NH-terminal kinase and p38 mitogen-activated protein kinase pathway in activated microglial cells. J Pharmacol Sci 116: 296–308.
- 14. Carmody RJ, Chen YH (2007) Nuclear factor-kappaB: activation and regulation during toll-like receptor signaling. Cell Mol Immunol 4: 31–41.
- 15. Guha M, Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13: 85–94.
- 16. Hong SS, Lee SA, Han XH, Jin HZ, Lee JH, et al. (2007) Kaurane diterpenoids from Isodon excisus inhibit LPS-induced NF-kappaB activation and NO production in macrophage RAW264.7 cells. J Nat Prod 70: 632–636.
- 17. Bonaiuto C, McDonald PP, Rossi F, Cassatella MA (1997) Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia. J Neuroimmunol 77: 51–56.
- 18. Couch Y, Alvarez-Erviti L, Sibson NR, Wood MJ, Anthony DC (2011) The acute inflammatory response to intranigral alpha-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation 8: 166.
- 19. Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, et al. (2002) Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 168: 4070–4077.
- 20. Ip JP, Nocon AL, Hofer MJ, Lim SL, Muller M, et al. (2011) Lipocalin 2 in the central nervous system host response to systemic lipopolysaccharide administration. J Neuroinflammation 8: 124.
- 21. Lee S, Kim JH, Seo JW, Han HS, Lee WH, et al. (2011) Lipocalin-2 Is a chemokine inducer in the central nervous system: role of chemokine ligand 10 (CXCL10) in lipocalin-2-induced cell migration. J Biol Chem 286: 43855–43870.
- 22. Roudkenar MH, Halabian R, Roushandeh AM, Nourani MR, Masroori N, et al. (2009) Lipocalin 2 regulation by thermal stresses: protective role of Lcn2/NGAL against cold and heat stresses. Exp Cell Res 315: 3140–3151.
- 23. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, et al. (2004) Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432: 917–921.
- 24. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, et al. (2002) The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 10: 1033–1043.
- 25. Zhang J, Wu Y, Zhang Y, Leroith D, Bernlohr DA, et al. (2008) The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol 22: 1416–1426.
- 26. Lee S, Lee J, Kim S, Park JY, Lee WH, et al. (2007) A dual role of lipocalin 2 in the apoptosis and deramification of activated microglia. J Immunol 179: 3231–3241.
- 27. Le W, Rowe D, Xie W, Ortiz I, He Y, et al. (2001) Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson’s disease. J Neurosci 21: 8447–8455.
- 28. Minghetti L, Levi G (1998) Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol 54: 99–125.
- 29. Wang W, Ji P, Dow KE (2003) Corticotropin-releasing hormone induces proliferation and TNF-alpha release in cultured rat microglia via MAP kinase signalling pathways. J Neurochem 84: 189–195.
- 30. Block ML, Li G, Qin L, Wu X, Pei Z, et al. (2006) Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. FASEB J 20: 251–258.
- 31. Brenneman DE, Gozes I (1996) A femtomolar-acting neuroprotective peptide. J Clin Invest 97: 2299–2307.
- 32. Boche D, Cunningham C, Docagne F, Scott H, Perry VH (2006) TGFbeta1 regulates the inflammatory response during chronic neurodegeneration. Neurobiol Dis 22: 638–650.
- 33. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML (2005) Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25: 1904–1913.
- 34. Rivest S (2006) Cannabinoids in microglia: a new trick for immune surveillance and neuroprotection. Neuron 49: 4–8.
- 35. Boche D, Cunningham C, Gauldie J, Perry VH (2003) Transforming growth factor-beta 1-mediated neuroprotection against excitotoxic injury in vivo. J Cereb Blood Flow Metab 23: 1174–1182.
- 36. Murphy S (2000) Production of nitric oxide by glial cells: regulation and potential roles in the CNS. Glia 29: 1–13.
- 37. Minghetti L (2004) Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63: 901–910.
- 38. St-Onge M, Flamand N, Biarc J, Picard S, Bouchard L, et al. (2007) Characterization of prostaglandin E2 generation through the cyclooxygenase (COX)-2 pathway in human neutrophils. Biochim Biophys Acta 1771: 1235–1245.
- 39. Baldwin AS Jr (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649–683.
- 40. Jung WK, Ahn YW, Lee SH, Choi YH, Kim SK, et al. (2009) Ecklonia cava ethanolic extracts inhibit lipopolysaccharide-induced cyclooxygenase-2 and inducible nitric oxide synthase expression in BV2 microglia via the MAP kinase and NF-kappaB pathways. Food Chem Toxicol 47: 410–417.
- 41. Oh YT, Lee JY, Lee J, Kim H, Yoon KS, et al. (2009) Oleic acid reduces lipopolysaccharide-induced expression of iNOS and COX-2 in BV2 murine microglial cells: possible involvement of reactive oxygen species, p38 MAPK, and IKK/NF-kappaB signaling pathways. Neurosci Lett 464: 93–97.
- 42. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA (1992) Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 175: 1181–1194.
- 43. Miharada K, Hiroyama T, Sudo K, Danjo I, Nagasawa T, et al. (2008) Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/macrophage lineage cells. J Cell Physiol 215: 526–537.
- 44. Devireddy LR, Gazin C, Zhu X, Green MR (2005) A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123: 1293–1305.
- 45. Devireddy LR, Teodoro JG, Richard FA, Green MR (2001) Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 293: 829–834.
- 46. Aigner F, Maier HT, Schwelberger HG, Wallnofer EA, Amberger A, et al. (2007) Lipocalin-2 regulates the inflammatory response during ischemia and reperfusion of the transplanted heart. Am J Transplant 7: 779–788.
- 47. Li C, Chan YR (2011) Lipocalin 2 regulation and its complex role in inflammation and cancer. Cytokine 56: 435–441.
- 48. Cowland JB, Sorensen OE, Sehested M, Borregaard N (2003) Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol 171: 6630–6639.
- 49. Caivano M (1998) Role of MAP kinase cascades in inducing arginine transporters and nitric oxide synthetase in RAW264 macrophages. FEBS Lett 429: 249–253.
- 50. Lu YC, Yeh WC, Ohashi PS (2008) LPS/TLR4 signal transduction pathway. Cytokine 42: 145–151.
- 51. Ashwell JD (2006) The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol 6: 532–540.
- 52. Da Silva J, Pierrat B, Mary JL, Lesslauer W (1997) Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes. J Biol Chem 272: 28373–28380.
- 53. Svensson CI, Marsala M, Westerlund A, Calcutt NA, Campana WM, et al. (2003) Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J Neurochem 86: 1534–1544.
- 54. Choi Y, Moon A, Kim YC (2008) A pinusolide derivative, 15-methoxypinusolidic acid from Biota orientalis inhibits inducible nitric oxide synthase in microglial cells: implication for a potential anti-inflammatory effect. Int Immunopharmacol 8: 548–555.